BioNTech (NASDAQ:BNTX) Receives “Outperform” Rating from BMO Capital Markets

BioNTech (NASDAQ:BNTX)‘s stock had its “outperform” rating restated by investment analysts at BMO Capital Markets in a report issued on Monday, MarketBeat reports.

Several other equities analysts have also recently commented on BNTX. Berenberg Bank assumed coverage on shares of BioNTech in a research note on Tuesday, November 19th. They set a “buy” rating and a $130.00 price objective for the company. The Goldman Sachs Group raised shares of BioNTech from a “neutral” rating to a “buy” rating and boosted their price objective for the company from $90.00 to $137.00 in a research note on Friday, November 8th. HC Wainwright reissued a “buy” rating and issued a $150.00 price target on shares of BioNTech in a research note on Monday, November 18th. Bank of America boosted their price target on shares of BioNTech from $125.00 to $150.00 and gave the stock a “buy” rating in a research note on Monday, September 16th. Finally, Evercore ISI raised shares of BioNTech from an “in-line” rating to an “outperform” rating and boosted their price target for the stock from $110.00 to $125.00 in a research note on Tuesday, November 19th. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $138.67.

BioNTech Trading Down 1.4 %

NASDAQ BNTX opened at $115.59 on Monday. The company’s 50 day moving average is $113.89 and its 200-day moving average is $98.94. BioNTech has a 12-month low of $76.53 and a 12-month high of $131.49. The company has a debt-to-equity ratio of 0.01, a current ratio of 7.33 and a quick ratio of 7.21.

BioNTech (NASDAQ:BNTX) last issued its quarterly earnings data on Monday, November 4th. The company reported $0.81 EPS for the quarter, beating the consensus estimate of ($1.26) by $2.07. The company had revenue of $1.24 billion during the quarter, compared to analysts’ expectations of $514.08 million. BioNTech had a negative net margin of 15.16% and a negative return on equity of 2.35%. BioNTech’s revenue for the quarter was up 38.9% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.73 earnings per share. Equities research analysts predict that BioNTech will post -3.72 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of BNTX. CANADA LIFE ASSURANCE Co increased its stake in shares of BioNTech by 79.6% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 3,426 shares of the company’s stock worth $316,000 after acquiring an additional 1,518 shares in the last quarter. Tidal Investments LLC purchased a new stake in BioNTech during the 1st quarter valued at about $703,000. EverSource Wealth Advisors LLC grew its position in BioNTech by 106.3% during the 1st quarter. EverSource Wealth Advisors LLC now owns 489 shares of the company’s stock valued at $43,000 after purchasing an additional 252 shares during the last quarter. GAMMA Investing LLC grew its position in BioNTech by 86.9% during the 2nd quarter. GAMMA Investing LLC now owns 512 shares of the company’s stock valued at $41,000 after purchasing an additional 238 shares during the last quarter. Finally, Granite Bay Wealth Management LLC purchased a new stake in BioNTech during the 2nd quarter valued at about $1,483,000. 15.52% of the stock is currently owned by institutional investors.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.